ASCO 2015 Highlights

Addition of Rituximab to Chemotherapy in Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor ALL: Results of the Randomized Graall-R 2005 Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory Ph+ ALL: Results from the Phase 2 ALCANTARA Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Long-Term Outcomes of Blinatumomab Treatment in Patients with MRD-Positive ALL

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Imatinib versus Dasatinib in Newly Diagnosed Chronic-Phase CML: Quality-of-Life Assessment in the NCRI SPIRIT2 Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory B-Precursor ALL Post-Allogeneic Hematopoietic Stem-Cell Transplantation

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Dose-Optimized Nilotinib in Patients with Newly Diagnosed CML-CP: Final Results from ENESTxtnd Study

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Effect of Nilotinib Treatment Duration on Treatment-Free Remission in CP-CML Patients Previously Treated with Imatinib: Interim Results of the ENESTPath Phase 3 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Multikinase Inhibitor Midostaurin in Newly Diagnosed AML Patients with FLT3 Mutations: Results of the CALGB 10603/RATIFY Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Allogeneic SCT After High versus Reduced-Intensity Conditioning in Patients with MDS or AML: Results of a Phase 3 BMT CTN 0901 Trial

ASH 2015 – Leukemia, ASH Highlights

Conference Correspondent

Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

ASH 2015 - Multiple Myeloma, ASH Highlights

Conference Correspondent

Page 177 of 329